biostudies-literatureFu PThe Canadian Institutes of Health ResearchJanssen Alzheimer Immunotherapy Research & Development, LLCLumosityDOD ADNIMerck & Co., Inc.Pfizer Inc.NIA NIH HHSCogstateIXICO Ltd.Meso Scale Diagnostics, LLCEisai Inc.National Institutes of HealthGE HealthcareNational Institute on AgingEli Lilly and CompanyCereSpir, Inc.FujirebioTransition TherapeuticsNovartis Pharmaceuticals CorporationTakeda Pharmaceutical CompanyEuroImmunFoundation for the National Institutes of HealthAlzheimer's Disease Neuroimaging InitiativeAraclon BiotechServierAlzheimer’s Drug Discovery FoundationNational Institute of Biomedical Imaging and BioengineeringElan Pharmaceuticals, Inc.Neurotrack TechnologiesBioClinica, Inc.AbbVieBristol-Myers Squibb CompanyCIHRPiramal ImagingNeuroRx ResearchAlzheimer’s AssociationGenentech, Inc.BiogenJohnson & Johnson Pharmaceutical Research & Development LLCF. Hoffmann-La Roche LtdLundbecke0274503https://www.ebi.ac.uk/biostudies/studies/S-EPMC9604923biostudies-literatureUnknown17(10)We aimed to examine the association of CSF tumor necrosis factor-alpha (TNFα) with conversion from mild cognitive impairment (MCI) to dementia. At baseline, there were a total of 129 participants with MCI in this study. The association of CSF TNFα levels with the incidence of dementia were evaluated using Cox proportional hazards regression analysis adjusted for potential confounders. Individuals were categorized into groups based on the CSF TNFα tertiles. Compared to the low group (the reference group), the intermediate group progressed more rapidly to dementia [HR (95% CI) = 2.2 (1.15-4.1); p = 0.016] after adjusting for other covariates. However, the high group did not progress faster than the low group [HR (95% CI) = 1.5 (0.79-2.8); p = 0.214]. Our study suggested a potential non-relationship between CSF TNFα levels and the risk of development of dementia among MCI older people.PloS oneCSF TNF α levels were associated with conversion from mild cognitive impairment to dementia.PMC9604923U01 AG024904W81XWH-12-2-0012Peng FFu PAlzheimer’s Disease Neuroimaging InitiativefalseCSF TNF α levels were associated with conversion from mild cognitive impairment to dementia.We aimed to examine the association of CSF tumor necrosis factor-alpha (TNFα) with conversion from mild cognitive impairment (MCI) to dementia. At baseline, there were a total of 129 participants with MCI in this study. The association of CSF TNFα levels with the incidence of dementia were evaluated using Cox proportional hazards regression analysis adjusted for potential confounders. Individuals were categorized into groups based on the CSF TNFα tertiles. Compared to the low group (the reference group), the intermediate group progressed more rapidly to dementia [HR (95% CI) = 2.2 (1.15-4.1); p = 0.016] after adjusting for other covariates. However, the high group did not progress faster than the low group [HR (95% CI) = 1.5 (0.79-2.8); p = 0.214]. Our study suggested a potential non-relationship between CSF TNFα levels and the risk of development of dementia among MCI older people.2022-01-01T00:00:00Z20222025-04-03T21:29:41.412Z2025-04-03T21:29:41.412ZS-EPMC96049233628838010.1371/journal.pone.0274503